Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONKO-005: Gemcitabine plus Erlotinib vs Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer
DRKS00000247Phase 3Active, not recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib, gemcitabine in pancreatic cancer (PC), sponsored by Charité – Universitätsmedizin Berlin. Started Mar 2010; status: active, not recruiting.
02
Drugs
erlotinibgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on DRKS00000247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000247.